Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01945034 · ClinicalTrials.gov registry record · Phase 3
5% Topical Ibuprofen (IBU) for Ankle Sprain
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT01945034 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 304 participants.
The verdict
NCT01945034, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated.
Interventions
- DRUG Placebo twice daily
- DRUG Topical IBU twice daily
- DRUG Topical IBU three times daily
- DRUG Placebo three times daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01945034
The ClinicalTrials.gov registry entry for NCT01945034 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo twice daily is the first listed.
NCT01945034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01945034 about?
NCT01945034 is a clinical study titled "5% Topical Ibuprofen (IBU) for Ankle Sprain". This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated.
What is the current status of trial NCT01945034?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2013-11. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01945034?
The interventions under investigation include: Placebo twice daily (DRUG), Topical IBU twice daily (DRUG), Topical IBU three times daily (DRUG), Placebo three times daily (DRUG).
Who is sponsoring clinical trial NCT01945034?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.